Low-intensity magnetic stimulation for treating major depression
Effects of Low-intensity Transcranial Magnetic Stimulation on Major Depressive Disorder, and on 5-hydroxyindoleacetic Acid and Brain-derived Neurotrophic Factor Levels
This study is testing whether low-intensity magnetic stimulation can help people with major depression feel better and change certain brain markers related to their mood.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Universidad de Guanajuato Academic / other |
| Locations | 1 site (León, Guanajuato) |
| Trial ID | NCT06667180 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effects of low-intensity transcranial magnetic stimulation (TMS) on patients with major depressive disorder (MDD). The study aims to determine whether TMS can reduce depressive symptoms and alter levels of specific biomarkers, including 5-hydroxyindoleacetic acid and brain-derived neurotrophic factor. Participants will undergo TMS treatment while their symptoms and biomarker levels are monitored before and after the intervention. The safety of the procedure will also be assessed through follow-up evaluations.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 60 with a diagnosed case of major depressive disorder who are currently receiving treatment.
Not a fit: Patients who are pregnant or have a history of epilepsy, schizophrenia, or certain medical implants may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new, non-invasive option for patients suffering from major depressive disorder.
How similar studies have performed: Previous studies have shown promise for TMS in treating depression, indicating that this approach is supported by existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age between 18 and 60 years. * Both sexes. * Those who have a diagnosis of MDD previously made by the treating psychiatrist (considering time since diagnosis and recurrence of episodes). * Those who continue with their respective treatment and attend follow-up consultations at the health facility. * Those who do not have a history of epilepsy, schizophrenia, neurosurgeries. * Those who do not have metal plates anywhere in the skull, neck, chest and shoulder. * Those who do not use pacemakers. * Those who do not take hormone substitutes. * Those who agree to participate in the research. Exclusion Criteria: * Those who are pregnant.
Where this trial is running
León, Guanajuato
- High Specialty Medical Unit No. 1, Bajío. Mexican Social Security Institute — León, Guanajuato, Mexico (Recruiting)
Study contacts
- Principal investigator: Olga E Escobar Florez, Master of Medical Sciences — Universidad de Guanajuato
- Study coordinator: Olga E Escobar Florez, Master of Medical Sciences
- Email: oe.escobarflorez@ugto.mx
- Phone: +524773703795
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.